table_1_The Prognostic Value of Immune Factors in the Tumor Microenvironment of Penile Squamous Cell Carcinoma.PDF
The host’s immune system plays a pivotal role in many tumor types, including squamous cell carcinomas (SCCs). We aim to identify immunological prognosticators for lymph node metastases (LNM) and disease-specific survival (DSS) in penile SCC. For this retrospective observational cohort study, penile SCC patients (n = 213) treated in the Netherlands Cancer Institute, were selected if sufficient formalin-fixed, paraffin-embedded tumor material was available. Analysis included previously described high-risk human papilloma virus (hrHPV) status, immunohistochemical scores for classical and non-classical human leukocyte antigen (HLA) class I, programmed death ligand-1 (PD-L1) expression, and novel data on tumor-infiltrating macrophages and cytotoxic an regulatory T-cells. Clinicopathological characteristics and extended follow-up were also included. Regression analyses investigated relationships of the immune parameters with LNM and DSS. In the total cohort, diffuse PD-L1 tumor-cell expression, CD163+ macrophage infiltration, non-classical HLA class I upregulation, and low stromal CD8+ T-cell infiltration were all associated with LNM. In the multivariable model, only tumor PD-L1 expression remained a significant predictor for LNM (odds ratio (OR) 2.8, p = 0.05). hrHPV negativity and diffuse PD-L1 tumor-cell expression were significantly associated with poor DSS and remained so upon correction for clinical parameters [hazard ratio (HR) 9.7, p < 0.01 and HR 2.8, p = 0.03]. The only immune factor with different expression in HPV+ and HPV− tumors was PD-L1, with higher PD-L1 expression in the latter (p = 0.03). In the HPV− cohort (n = 158), LNM were associated with diffuse PD-L1 tumor-cell expression, high intratumoral CD163+ macrophage infiltration, and low number of stromal CD8+ T-cells. The first two parameters were also linked to DSS. In the multivariable regression model, diffuse PD-L1 expression remained significantly unfavorable for DSS (HR 5.0, p < 0.01). These results emphasize the complexity of the tumor microenvironment in penile cancer and point toward several possible immunotherapy targets. Here described immune factors can aid risk-stratification and should be evaluated in clinical immunotherapy studies to ultimately lead to patient tailored treatment.
History
References
- https://doi.org//10.1002/ijc.31194
- https://doi.org//10.1016/j.urolonc.2006.08.029
- https://doi.org//10.1111/bju.12993
- https://doi.org//10.1159/000358370
- https://doi.org//10.1016/j.urolonc.2012.04.017
- https://doi.org//10.1016/j.juro.2014.08.087
- https://doi.org//10.1007/s00428-014-1713-4
- https://doi.org//10.1016/j.juro.2014.11.057
- https://doi.org//10.1007/s13277-014-2864-2
- https://doi.org//10.1016/j.juro.2016.09.088
- https://doi.org//10.1016/j.humpath.2016.09.003
- https://doi.org//10.1093/annonc/mdw216
- https://doi.org//10.1080/2162402X.2016.1269047
- https://doi.org//10.1038/nrclinonc.2017.101
- https://doi.org//10.1126/science.aaf2834
- https://doi.org//10.18632/oncotarget.14796
- https://doi.org//10.1080/2162402X.2017.1356148
- https://doi.org//10.3109/00016489.2016.1164341
- https://doi.org//10.4161/21624011.2014.965570
- https://doi.org//10.1038/bjc.2011.189
- https://doi.org//10.1111/j.1600-0897.2008.00590.x
- https://doi.org//10.1007/s12105-016-0776-8
- https://doi.org//10.18632/oncotarget.9130
- https://doi.org//10.1111/jgh.13342
- https://doi.org//10.1007/s00262-016-1805-x
- https://doi.org//10.1158/2159-8290.CD-15-1545
- https://doi.org//10.1186/1479-5876-9-204
- https://doi.org//10.1080/2162402X.2015.1049804
- https://doi.org//10.1016/j.cell.2010.03.014
- https://doi.org//10.1016/j.it.2007.09.004
- https://doi.org//10.1111/jop.12643
- https://doi.org//10.7150/jca.21444
- https://doi.org//10.1016/j.eururo.2007.01.107
- https://doi.org//10.1016/S0959-8049(98)00151-8
- https://doi.org//10.1038/modpathol.2017.111
- https://doi.org//10.1007/s00428-016-1910-4
- https://doi.org//10.1016/j.juro.2009.04.028
- https://doi.org//10.1111/his.13205
- https://doi.org//10.1007/s00428-014-1630-6
- https://doi.org//10.1016/j.jaad.2012.12.973
- https://doi.org//10.1097/PAS.0000000000000124
- https://doi.org//10.1158/1078-0432.CCR-15-0244
- https://doi.org//10.1126/scitranslmed.3003689
- https://doi.org//10.1001/jamaoncol.2015.6326
- https://doi.org//10.1016/j.celrep.2017.04.031
- https://doi.org//10.1172/jci.insight.93652
- https://doi.org//10.4049/jimmunol.1100889
- https://doi.org//10.1016/j.cell.2015.03.030
Usage metrics
Read the peer-reviewed publication
Categories
- Transplantation Immunology
- Tumour Immunology
- Immunology not elsewhere classified
- Immunology
- Veterinary Immunology
- Animal Immunology
- Genetic Immunology
- Applied Immunology (incl. Antibody Engineering, Xenotransplantation and T-cell Therapies)
- Autoimmunity
- Cellular Immunology
- Humoural Immunology and Immunochemistry
- Immunogenetics (incl. Genetic Immunology)
- Innate Immunity